Oxford Immunotec Schedules Third Quarter 2018 Earnings Release and Business Update Conference Call for November 9, 2018

Udgivet den 06-11-2018  |  kl. 22:12  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, Rick Altieri, Chief Financial Officer, and Karen Koski, Vice President, Strategy and Investor Relations will host a conference call to review the Company's third quarter 2018 financial results and provide a business update at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 7673307, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Karen Koski
VP, Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Vestas får 50 megawatt-ordre i Sydkorea
Aktier/tendens: Bavarian og Nilfisk kan få genrejsning i positiv start
Aktier/middag: Bavarian Nordic tager revanche i splittet og lettere negativt C25
Bavarian Nordic: Farlig variant af mpox konstateret for første gang i USA
Bavarian får løftet kursmålet til 360 kr. fra 345 kr. af Nordea efter vildt kursfald
 

Seneste nyheder

17:56 Europa/aktier: Ejendomsaktier tyngede mens Bavarian toppede i næsten uændret Stoxx 600
17:21 H+H får skåret kursmålet med en femmer af ABG forud for regnskab
17:18 Markedsoversigt: Zealand og Vestas faldt mest i rødt C25 mens renter steg
17:04 Mandagens aktier: Zealand og Vestas faldt mest i rødt C25 mens Bavarian fik revanche
17:02 Mandagens obligationer: Renter tikkede op på dag med fokus på taler
16:54 Trumps rådgivere åbner for tidligere centralbankdirektør som finansminister
16:27 Nvidias regnskab kan blive ugens begivenhed: Strateg stiller særligt skarpt på tre ting
15:44 USA/åbning: Tesla får flyvende start på ugen i ellers afdæmpet marked
14:42 Græsk ECB-medlem: Rentesænkning i december er nærmest stensikker
14:22 USA/tendens: Rolig start i vente på uge med fokus på Nvidia
14:08 Novo Nordisk lancerer Wegovy i Kina
14:07 Tørlastindekset Baltic Dry falder med 1,6 pct. til 1756 point
13:35 Tesla fortsætter optur: Trump afsøger mulig lempelse af regler for selvkørende biler
13:16 Sønderslået AI-aktie stiger frem mod deadline for indsendelse af årsregnskab
12:48 Europa/aktier: Dansk selskab topper i lettere negativt Stoxx 600
12:46 Nordea fuldender opkøb af Danske Banks norske privatkunde- og private banking-forretning
12:36 Nvidia går rød dag i møde efter rygter om overophedning i ny chip
12:30 Spirit Airlines indgiver konkursbegæring
12:15 Obligationer/middag: Danske renter følger med udlandet op
11:39 Donald Trump udpeger "big tech"-kritiker til FCC-formandsposten